Kinetic‐pharmacodynamic model of platelet time course in patients with moderate‐to‐severe atopic dermatitis treated with oral Janus kinase 1 inhibitor abrocitinib
E Soto, C Banfield, P Gupta… - CPT: Pharmacometrics …, 2020 - Wiley Online Library
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
[HTML][HTML] Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor …
E Soto, C Banfield, P Gupta… - CPT: Pharmacometrics & …, 2020 - ncbi.nlm.nih.gov
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor …
E Soto, C Banfield, P Gupta… - CPT: Pharmacometrics …, 2020 - search.ebscohost.com
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor …
E Soto, C Banfield, P Gupta… - CPT: Pharmacometrics …, 2020 - search.proquest.com
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
E Soto, C Banfield, P Gupta… - CPT: Pharmacometrics & …, 2020 - europepmc.org
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
E Soto, C Banfield, P Gupta… - CPT: pharmacometrics …, 2020 - pubmed.ncbi.nlm.nih.gov
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo-controlled, randomized, double-blind, phase IIb trial (dose …
dermatitis (AD) in a placebo-controlled, randomized, double-blind, phase IIb trial (dose …